text_1: Pyridostatin decreases telomere fragility in BRCA2-deficient cells.
text_2: Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.